Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)- 1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348)

Journal of Medicinal Chemistry

Volumn 51, Issue 6, 2008, Pages 1861-1873

  Fensome, Andrew ^a   Adams, William R ^a   Adams, Andrea L ^a   Berrodin, Tom J ^a   Cohen, Jeff ^a   Huselton, Christine ^a   Illenberger, Arthur ^a   Kern, Jeffrey C ^a   Hudak, Valerie A ^a   Marella, Michael A ^a   Melenski, Edward G ^a   McComas, Casey C ^a   Mugford, Cheryl A ^a   Slayden, Ov D ^b   Yudt, Matthew ^a   Zhang, Zhiming ^a   Zhang, Puwen ^a   Zhu, Yuan ^a   Winneker, Richard C ^a   Wrobel, Jay E ^a  

^a PFIZER INC   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (3,3 DIMETHYL 2 OXO 2,3 DIHYDRO 1H INDOL 5 YL) 1 METHYL 1H PYRROLE 2 CARBONITRILE; 5 (7 FLUORO 3,3 DIMETHYL 2 OXO 2,3 DIHYDRO 1H INDOL 5 YL) 1 METHYL 1H PYRROLE 2 CARBONITRILE; ANTIGESTAGEN; OXINDOLE; PROGESTERONE RECEPTOR MODULATOR; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; WAY 255348;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN CELL; MENSTRUATION; MONKEY; NONHUMAN; OVULATION INHIBITION; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ALKALINE PHOSPHATASE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FEMALE; HUMANS; INDOLES; MACACA FASCICULARIS; MACACA MULATTA; MOLECULAR STRUCTURE; OVULATION; PYRROLES; RATS; RECEPTORS, PROGESTERONE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 41149102488     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701080t     Document Type: Article

References (36)

1. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schuetz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M. The nuclear receptor superfamily: The second decade. Cell 1995, 83 (6), 835-839.
2. Brown, A.; Cheng, L.; Lin, S.; Baird, D. T. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J. Clin. Endocrinol. Metab. 2002, 87 (1), 63-70.
3. von Hertzen, H.; Van Look, P. F. A. Antiprogestins for contraception. Semin. Reprod. Med. 2005, 23 (1), 92-100.
4. Chwalisz, K.; DeManno, D.; Garg, R.; Larsen, L.; Mattia-Goldberg, C.; Stickler, T. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin. Reprod. Med. 2004, 22 (2), 113-119.
5. Chwalisz, K.; Larsen, L.; Mattia-Goldberg, C.; Edmonds, A.; Elger, W.; Winkel Craig, A. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil. Steril. 2007, 87 (6), 1399-1412.
6. Fedele, L.; Berlanda, N. Emerging drugs for endometriosis. Exp. Opin. Emerging Drugs 2004, 9 (1), 167-177.
7. Kettel, L. M.; Murphy, A. A.; Morales, A. J.; Yen, S. S. C. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am. J. Obstet. Gynecol. 1998, 178 (6), 1151-1156.
8. Kettel, L. M. Treatment of endometriosis with mifepristone (RU486). Int. Congr., Symp. Semin. Ser. 1997, 13 (Endometriosis Today), 334-338.
9. Schreiber, C.; Creinin, M. Mifepristone in abortion care. Semin. Reprod. Med. 2005, 23 (1), 82-91.
10. Kloosterboer, H. J.; Deckers, G. H.; de Gooyer, M. E.; Dijkema, R.; Orlemans, E. O. M.; Schoonen, W. G. E. J. Pharmacological properties of a new selective antiprogestagen: Org 33628. Ann. N.Y. Acad. Sci. 1995, 761 (Steroid Receptors and Antihormones), 192-201.
11. DeManno, D.; Elger, W.; Garg, R.; Lee, R.; Schneider, B.; Hess-Stumpp, H.; Schubert, G.; Chwalisz, K. Asoprisnil (J867): A selective progesterone receptor modulator for gynecological therapy. Steroids 2003, 68 (10-13), 1019-1032.
12. Osipo, C.; Jordan, V. C. SERMS (selective estrogen receptor modulators). Encycl. Endocr. Dis. 2004, 4, 221-228.
13. Redden, P. R. Selective estrogen receptor modulators, pure antiestrogens and related estrogen receptor ligands. Exp. Opin. Ther. Pat. 2004, 14 (3), 337-353.
14. Goldstein, S. R.; Siddhanti, S.; Ciaccia, A. V.; Plouffe, L., Jr. A pharmacological review of selective oestrogen receptor modulators. Hum. Reprod. Update 2000, 6 (3), 212-224.
15. Lloyd, D. G.; Meegan, M. J. Recent advances in estrogen receptor antagonists. IDrugs 2000, 3 (6), 632-642.
16. Winneker, R. C.; Fensome, A.; Wrobel, J. E.; Zhang, Z.; Zhang, P. Nonsteroidal progesterone receptor modulators: Structure activity relationships. Semin. Reprod. Med. 2005, 23 (1), 46-57.
17. Zhang, P.; Fensome, A.; Wrobel, J.; Winneker, R.; Zhang, Z. Non-steroidal progesterone receptor-modulators. Exp. Opin. Ther. Pat. 2003, 13 (12), 1839-1847.
18. Fensome, A.; Koko, M.; Wrobel, J.; Zhang, P.; Cohen, J.; Lundeen, S.; Rudnick, K.; Zhu, Y.; Winneker, R.; Zhang, Z., Novel 5-Aryl-1,3-dihydro-indole- 2-thiones: Potent, orally active progesterone receptor agonists. Abstr. Pap. - Am. Chem. Soc. 2002, 223,MEDI-069.
19. Collins, M. A.; Hudak, V.; Bender, R.; Fensome, A.; Zhang, P.; Miller, L.; Winneker, R. C.; Zhang, Z.; Zhu, Y.; Cohen, J.; Unwalla, R. J.; Wrobel, J. Novel pyrrole-containing progesterone receptor modulators. Bioorg. Med. Chem. Lett. 2004, 14 (9), 2185-2189.
20. Fensome, A.; Bender, R.; Chopra, R.; Cohen, J.; Collins, M. A.; Hudak, V.; Malakian, K.; Lockhead, S.; Olland, A.; Svenson, K.; Terefenko, E. A.; Unwalla, R. J.; Wilhelm, J. M.; Wolfrom, S.; Zhu, Y.; Zhang, Z.; Zhang, P.; Winneker, R. C.; Wrobel, J. Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal progesterone receptor agonist Tanaproget. J. Med. Chem. 2005, 48 (16), 5092-5095.
21. Fensome, A.; Bender, R.; Cohen, J.; Collins, M. A.; Mackner, V. A.; Miller, L. L.; Ullrich, J. W.; Winneker, R.; Wrobel, J.; Zhang, P.; Zhang, Z.; Zhu, Y. New progesterone receptor antagonists: 3,3-disubstituted-5- aryloxindoles. Bioorg. Med. Chem. Lett. 2002, 12 (23), 3487-3490.
22. Fensome, A.; McComas, C. C.; Melenski, E. G.; Marella, M. A.; Wrobel, J. E.; Grubb, G. S. Progesterone receptor modulators comprising pyrrole-oxindole derivatives, their preparation and use as contraceptives and in treating hormone-related conditions. U.S. Patents 2005-175824, 2006030717, 20050706, 2006.
23. Kende, A. S.; Hodges, J. C. Regioselective C-3 alkylations of oxindole dianion. Synth. Commun. 1982, 12 (1), 1-10.
24. Littke, A. F.; Dai, C.; Fu, G. C. Versatile catalysts for the Suzuki cross-coupling of arylboronic acids with aryl and vinyl halides and triflates under mild conditions. J. Am. Chem. Soc. 2000, 122 (17), 4020-4028.
25. Zhang, Z.; Lundeen, S. G.; Zhu, Y.; Carver, J. M.; Winneker, R. C. In vitro characterization of trimegestone: A new potent and selective progestin. Steroids 2000, 65 (10-11), 637-643.
26. Boehm, H.-J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Mueller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry. ChemBioChem 2004, 5 (5), 637-643.
27. Sadowski, I.; Bell, B.; Broad, P.; Hollis, M. GAL4 fusion vectors for expression in yeast or mammalian cells. Gene 1992, 118 (1), 137-141.
28. Zhang, Z.; Funk, C.; Glasser, S. R.; Mulholland, J. Progesterone regulation of heparin-binding epidermal growth factor-like growth factor gene expression during sensitization and decidualization in the rat uterus: Effects of the antiprogestin, ZK 98.299. Endocrinology 1994, 135 (3), 1256-1263.
29. Chillik, C. F.; Hsiu, J. G.; Acosta, A. A.; Van Uem, J. F. H. M.; Hodgen, G. D. RU486-induced menses in cynomolgus monkeys: Uniformity of endometrial sloughing. Fertil. Steril. 1986, 45 (5), 708-712.
30. Verbost, P. M.; Hanssen, R. G. J. M.; Korver, G. H. V.; Mulders, T. M. T. ORG 33628 and ORG 31710 to control vaginal bleeding in progestin-only contraceptive regimens. Semin. Reprod. Med. 2005, 23 (1), 101-111.
31. Batista, M. C.; Cartledge, T. P.; Zellmer, A. W.; Nieman, L. K.; Merriam, G. R.; Loriaux, D. L. Evidence for a critical role of progesterone in the regulation of the midcycle gonadotropin surge and ovulation. J. Clin. Endocrinol. Metab. 1992, 74 (3), 565-570.
32. Danielsson, K. G.; Swahn, M. L.; Westlund, P.; Johannisson, E.; Seppala, M.; Bygdeman, M. Effect of low daily doses of mifepristone on ovarian function and endometrial development. Hum. Reprod. 1997, 12 (1), 124-131.
33. Heikinheimo, O.; Gordon, K.; Williams, R. F.; Hodgen, G. D. Inhibition of ovulation by progestin analogs (agonists vs. antagonists): preliminary evidence for different sites and mechanisms of actions. Contraception 1996, 53 (1), 55-64.
34. Slayden, O. D.; Chwalisz, K.; Brenner, R. M. Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. Hum. Reprod. 2001, 16 (8), 1562-1574.
35. Slayden, O. D.; Zelinski-Wooten, M. B.; Chwalisz, K.; Stouffer, R. L.; Brenner, R. M. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum. Reprod. 1998, 13 (2), 269-277.
36. Arey, B. J.; Deecher, D. C.; Shen, E. S.; Stevis, P. E.; Meade, E. H., Jr.; Wrobel, J.; Frail, D. E.; Lopez, F. J. Identification and characterization of a selective, nonpeptide follicle-stimulating hormone receptor antagonist. Endocrinology 2002, 143 (10), 3822-3829.